🎁 Black Friday: 50% off Unlimited and 30% off Pro annual plans
MaxCyte, Inc. (MXCT)
NASDAQ: MXCT · Real-Time Price · USD
1.370
+0.090 (7.03%)
At close: Nov 20, 2026, 4:00 PM EST
1.350
-0.020 (-1.46%)
After-hours: Nov 20, 2026, 7:03 PM EST
← View all transcripts

2026 Stephens Annual Investment Conference | NASH2026

Nov 18, 2026

Summary

Akron expands the portfolio across viral and non-viral cell therapy, with revenue synergies expected from 2028. Core growth, rising royalties, and cost controls support a 2027 cash-burn target below $10M and a path toward cash-flow positivity.

Moderator

Good morning, and welcome to day two of the Stephens Conference. I'm Hannah Raiford. I'm on the life science tools and pharma services team here at Stephens, and today I'm pleased to be joined by MaxCyte's team. We have CEO Maher Masoud and CFO Parmeet Ahuja. Welcome. I guess I'll turn it over to you, Maher, if you have any opening comments, and then we can launch into Q&A.

Maher Masoud
CEO, MaxCyte

Absolutely. Hannah, thank you for having us back. We were here last year, so great conference. Appreciate being here. I just want to open a few remarks as well. If I recall last year, same time, we talked about going into that 2026 time period. There were headwinds that we were dealing with back in 2025 from some of our customer programs that were just rationalizing. The whole cell therapy space felt like it was rationalizing. 2026, we had a goal coming in 2026, which was get back to growth in the second half of the year, continue to maximize the efficiencies of the organization, and really expand our product offerings. I think we're hitting all three going into this year, going into next year. We announced our Q3 earnings last week, where we upped the guide again to $34.5 million of total revenue. Obviously, there's big news.

We acquired Akron, a leading cytokine growth factor reagent company that's been in the space for 20-plus years that we're extremely excited about. We're bringing a leadership team there as well on the Akron acquisition that we can get into. But truly, we're just hitting all the metrics that we wanted. Get back to growth the second half of the year. We knew first half would have a tough comp. Expand our product offerings, which we've done now, and just really position us for the growth of cell therapy in that 2027, 2028, 2029, and really outer years as well, from a very healthy cost basis. I think we're hitting on all those metrics. So thanks for having us.

Moderator

Yeah. All right. To kick things off, I think the biggest news recently is obviously the Akron acquisition. There've been lots of changes recently that nearly doubles annual revenue. It expands the customer base and the business pretty meaningfully into other areas. Can you just talk broadly about the strategic focus for MaxCyte from here and any changes in how MaxCyte's going to operate going forward?

Maher Masoud
CEO, MaxCyte

Sure. Absolutely. Great question. MaxCyte has been an electroporation company focused on the non-viral cell therapy space since its inception, and we are continuing to build on that. What Akron does for us really expands us into the entire cell therapy workflow, not just non-viral, but also viral. In addition, as you mentioned, where it nearly doubles our revenue, it also brings to us a few things that we have not had in the past.

One is, it is complementary in the non-viral space. So their cytokines and growth factors are sold before, they are used before and after the engineering step on our system. That is something we can really commercialize and use our commercial team that we have built over the last few years to truly boost the revenues that Akron can bring. But it also gets us into the viral space as well. So overnight, our addressable market truly increases.

We go from supporting half of the cell therapy space roughly to the entire cell therapy space, so 770-plus programs, so to speak. It also just positions us where we have talked about the goal that I had was cell therapy, I have always said, is the future of medicine. That has not changed, and we are seeing that still. You are seeing commercial therapies come to light. Akron brings that to us as well, where we now are embedded in the entire cell therapy space. Overnight, we are embedded now in five, once we close the deal, in five commercial therapies. We have one we are supporting right now. We anticipate at least another one next year from us. But they have four that they are supporting currently, and they have another four in phase III that potentially can be improved in the near term as well.

Extremely durable revenue that it brings to us, Hannah. Their commercial revenue is about 40%-45% of their current revenue. These are locked in, specked in agreements. So really, it positions us to become a true cell therapy provider above and beyond just electroporation while we continue to build upon the non-viral electroporation platform as well.

Moderator

For those that are less familiar with MaxCyte, and then obviously you have this new acquisition, can you just explain the key product offerings in electroporation, but then also the products that Akron and SeQure Dx add to that?

Maher Masoud
CEO, MaxCyte

Sure. Absolutely. The key product offerings for MaxCyte's electroporation is we have a seamless, all the way we can take you from research to cGMP clinical and commercial product offerings. We're on our electroporation platform. We can take cell therapies and cell therapy providers from early discovery, from our research systems, all the way to cGMP and commercial in a seamless optimized process. Not many companies can do that. In fact, we launched earlier this year the system called the DTx. Our cGMP system is called the GTx. The DTx is actually even earlier in research. It's discovery, where we can work with the same protocols with therapeutic developers on their science and ensure that the protocols that we optimize early in research and discovery, they can take seamlessly into the clinic. We've done that. We're getting good traction within DTx and our other systems as well.

We have the ATx that gets you closer to the clinic as well. We are really a true unique company in the sense of we have 13 clinical programs right now using our GTx in the clinic. Obviously, one approved program, which is CASGEVY. They use our system to engineer the cells. Those 13 programs are amongst 12 companies. These are the lead programs they're using our system for. We do it under a model that's different than most companies, which is we have the SPL model that allows us to have economics on the commercial success of any therapy. At least a 1% royalty on commercial products. We receive milestones through the clinical development of these products, and then we also receive annual lease fees from the systems being used in engineering of these cells as well, in addition to the recurring consumable revenue as well.

Obviously, for Akron, what it brings is above and beyond that. They have a truly unique differentiator product. Their cytokines and growth factors come in a liquid format that can be stable 12 months plus at refrigerated temperatures. No one else has that. It's unique to them, they developed. Then they have a closed system solution that they've patented. Those liquid cytokines can come in a liquid format in closed system bags that can be bio-welded into the manufacturing process. Again, sitting at stable 12 months plus stability at refrigerant temperatures. No one else has that either. Those cytokines and growth factors are used before and after electroporation. It's also used before and after any viral engineering, if you're not using electroporation. That's really what's been embedded in these four commercial programs, and they're specced into 95 clinical programs as well.

Again, using these cytokines, growth factors, and the human plasma products as well. Truly a unique offering that no one else has. Very similar to us, just like our system used in clinic, developers reference a master file, it's called the DMF, Drug Master File. For their cytokines and growth factors, they also reference Akron's Drug Master File as well. So it becomes embedded in the product, it's specced into the regulatory process, specced into the cell therapy manufacturing process, where the FDA or the EMA or equivalent regulatory bodies reference their cytokines, growth factors in there as well. Obviously, SeQure Dx brings the ability for us to do off-target assessment of cells being engineered for safety and regulatory purposes. We have a true offering now, a breadth of offering to help developers engineer cell therapies.

Moderator

Mm-hmm. This kind of expands you from an electroporation company to more of a broad cell therapy solutions company. What made this the right time to add Akron, and what makes that a good fit for you all?

Maher Masoud
CEO, MaxCyte

Absolutely. The right time really is when you find an organization like Akron. I've known them for quite some time. The Head of Operations there, Ezequiel Zylberberg, has been with them, helped them grow over the years as a 20-plus-year-old company. He will take over as Head of Global Akron once the acquisition closes. They have an industry veteran there as well, Dave Smith, who's been a former Lonza, Cambrex guy. He's grown up in the cell therapy space, knows it very well, has really helped grow that company since he joined them years ago. He will remain on as President and Chief Commercial Officer as well. But really, it's their breadth of offering, Hannah, is what it brings to us. It's a unique organization. The acquisition itself was a highly competitive process. It was not just us bidding. We actually were not even the highest bidders.

But there's a reason why these two companies come together and make the most sense, right? It's in essence a cell therapy tools company now that can truly become embedded in the commercial products in two different avenues, through the engineering steps, through the activation and expansion steps, through the fill finish steps as well. It just made perfect sense. It's very complementary to us. In addition to that, they've run a very lean organization very smartly. The majority of their focus has been in the U.S., really on viral cell therapies, because that's where the space was early. We have a global commercial team, so we can expand their presence in Europe, expand their presence in Asia Pacific, where a lot of therapies are also being developed as well.

It makes us deeper into the cell therapy non-viral space by now providing those offerings before and after our engineer step, and it expands our offering, where now we're part of the entire cell therapy space in the viral market as well. It's just a win-win. It's complementary business. I could not be more excited. This is why now, and when you find these kind of opportunities where two companies can truly help the industry grow and come together as one, it just makes perfect sense.

Moderator

Yeah. Akron's GMP cytokines and growth factors compete with some pretty large players like Sartorius, Thermo Fisher, Bio-Techne. Can you just expand a little bit on how Akron is able to compete with them and differentiate?

Maher Masoud
CEO, MaxCyte

Absolutely. Very similar to MaxCyte, we compete with some of those names as well. What they do is highly differentiated products. As I mentioned earlier, they have liquid cytokines that are sitting in a closed system solution bags that can bio-weld into the manufacturing process. These liquid cytokines, unlike those that you mentioned, they come at refrigerant temperatures, so they're highly stable, 12 months plus. No one has that ability. Their closed system solution is patented. The process itself, the formulation itself is proprietary to Akron. Really, if you think about it from a manufacturing perspective, you hear the words about automating manufacturing, right? Reducing cost of manufacturing. Well, you do that by having products that are automatable, products that can go into the manufacturing process. Only Akron has them. Only Akron has it. Some of those competitors obviously have their own cytokines, growth factors.

Oftentimes, if anybody does have a liquid format, it comes in a freezer, so it has to be frozen, and it's not as stable. The closed system liquid bag solution sitting in those bags that can bio-weld, that's truly unique to Akron. So it's a unique offering that we believe with our commercial team, we can begin to really, truly help them expand even outside the U.S.

Moderator

You talked a little bit about some of the cross-selling opportunities. Can you just talk about any revenue synergies that you kind of see with this?

Maher Masoud
CEO, MaxCyte

Absolutely. I will let Parmeet speak to that as well. We have built in very little initial revenue synergies, but Parmeet, if you want to speak to that, and then I can elaborate as well.

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, as Maher mentioned, we benefit on the MaxCyte side with a pretty established commercial infrastructure in both Europe and Asia, where Akron has not had a big presence. Most of their revenues are from the U.S. So we certainly see, Hannah, revenue synergies shaping up over the years. First year is going to be very light touch, really exchanging leads between the two teams and such. We are not building really hardly any synergies here in 2027. We will start to see some in 2028, and then more of an uptick in 2029. The customer life cycle is also such where you will approach the customers at a preclinical stage, and then as their program progresses, the real growth in revenue shows up when the product goes commercial. So certainly expect to see that in the two to three-year timeframe, nice revenue synergies.

Moderator

Awesome. As it relates to cost synergies, I think you have cited $3 million-$4 million of cost synergies, and you are targeting low 70s gross margin for the combined company. Is there room for any more costs to be taken out after this? Is this kind of the initial look, or what did I see there?

Parmeet Ahuja
CFO, MaxCyte

Yeah, very good question. So $3 million-$4 million, typical corporate consolidation, operational efficiencies that come from a typical integration. Our focus will be on that and achieving that in 2027. Obviously, Akron comes with a very good, healthy mid-60s gross margins, complemented now with MaxCyte's high 70s. The combined company will be in the low 70s, very attractive gross margin profile. As the integration progresses, Hannah, you are spot on. We will continue to look for opportunities, but more of that to come in the 2028 timeframe. Our focus in 2027 will remain sort of committed to the number we have put out. Along with those efficiencies, we expect MaxCyte cash burn to drop from exiting this year, $17 million, to less than $10 million next year.

Moderator

Hannah, last one on Akron before I move on to the broader company. It seems like these revenues are pretty sticky. You talked about it being specced into four commercially approved therapies. At what stage of the clinical process are these typically specced in? Given MaxCyte's strong early-stage relationships on the electroporation side, do you see much of an opportunity to be able to convert some of these customers over to Akron?

Maher Masoud
CEO, MaxCyte

Absolutely, Hannah. To speak when they get specced in, and specced in meaning that is when they become part of that clinical manufacturing process, the reagents begin, are now referenced as part of the DMF and the regulatory filings. That is at that really early clinical stage or preclinical stage, right before a company is about to file their IND or IND equivalent outside the U.S.

That is where we have the opportunity. If you look at what we have built here as an organization at MaxCyte side, we have a global sales and FAS team. Our field application scientists sit next to our BDMs, our sales reps, and this opportunity for us to really go in there and begin to optimize the cytokines from growth factors, these best-in-class growth factors and cytokines from Akron, optimize into the process, spec them into that process, and that is a huge opportunity for us.

Enormous opportunity. I mean, we are already touching a vast majority of the customers and the therapies out there. We now have the ability to truly boost them from that perspective and spec them in before they get into the clinic. Once you are in the clinic, it becomes very tough to be specced out because you are part of the manufacturing process.

Your DMF is referenced as part of the regulatory filing. You can imagine on the non-viral side, where they would be speccing in our product, the electroporation side, they are referencing our master file. They are referencing Akron's master file. We now become a much bigger portion of the regulatory filing as well. So a true opportunity to really get in there early in the preclinical process, early in the clinical process, and begin to start to really get the traction that I think we can provide to Akron.

Moderator

Yeah, that is great. All right. Finally moving past Akron.

There's been a number of macro headwinds in the life science tools space that's impacted your core electroporation business, but it seems like we've finally started to kind of hit an inflection point over the last couple quarters. Can you just talk about what you're seeing in terms of demand across instruments, consumables, and licenses, and how do you see these kind of playing out into 2027?

Maher Masoud
CEO, MaxCyte

You want me to talk about the market headwinds or the And then from there, and then you talk about the consumables and everything else. From a macro environment, Hannah, we're seeing there's continued stability. If you look at where we were in 2024, let's take a step back. In 2021 is where VC-funded cell therapy programs were at their peak. Those days are not coming back, but we don't want them to come back. That was kind of a bit of a bubble for the cell therapy market. 2024 funding was about $3 billion overall, across 126 programs, roughly. 2025 funding was more than that, about 19% more, about $3.5 billion. 2026 is looking to be a little bit more than 2025, on par with that. What we're seeing, though, is programs are funded as they are more late stage.

The late-stage programs are what's getting funded. The early-stage ones, obviously, unless you can show efficacy or you can show true proof point, it's a little bit tougher to get funded. An example we bring up is, a great company, one of our partners is Allogene. They have a phase III program, and they received funding, I believe, of over $150 million just a few months ago. So those are the kind of programs being funded late stage, and that's what you want to see. And it builds very nicely in our model, but with our model and Akron's model, I'll get back to it again, which is the more you are specced in and embedded in these late-stage clinical programs, the more of a chance you have to be embedded in commercial programs. That's where your revenue growth starts to happen.

Parmeet, did you want to elaborate on where we see the consumables and-

Parmeet Ahuja
CFO, MaxCyte

Yeah, absolutely.

I mean, Q3 certainly, core revenue was up 27%. Hannah, as you saw, growth was across the portfolio, SPL and non-SPL customers. PA revenue grew 20%. If you look at PA revenue trailing 12 months, we are at mid-single digits, very healthy. Instruments had a very strong quarter. Great funnel conversion by our sales team, with and without contributions from the Genentech partnership. As we look ahead, we are going to be growing next year from the stable base. I expect PA revenue to be right in that range of mid-single digit growth to continue. Licenses tend to be very stable, kind of in that same growth rate. Instruments, as our team continues to convert very strongly, I think will kind of follow that same path of mid to high single. You are seeing the benefit of operating leverage show up in our P&L.

We have kept a very nice tight lid on operating expenses. Net losses were down almost 50% year to date, year- on- year. You will continue to see the benefit of that operating leverage as we move forward.

Moderator

There seems like there is still a bit of a split between funding for later stage assets and earlier stage cell and gene therapy assets. I think you kind of called out some of that.

But can you just talk about what you are seeing in your customer base specifically? Are there still pockets of weakness that you would call out that you might see coming back in the next year or so?

Maher Masoud
CEO, MaxCyte

Yeah, pockets of weakness. I mean, obviously, earlier stage programs, they are still having a hard time being funded. I would say not so much to focus on earlier stage or pockets of weakness. What we are seeing actually is earlier stage programs in academia clinical trials are expanding. We are seeing that. So, you are actually seeing academic clinical trials really take effect. We began to actually target those trials in that late 2024, 2025 period, realizing that that can kind of seed the market as well for future industry trials as well.

So, that is where we are seeing pockets that previously maybe were not as strong, that we are starting to see really inroads there, from that perspective. If you are talking about what we are seeing in terms of maybe broader than that or some of the indications, so to speak, obviously autologous are still dominating the autologous versus allogeneic market.

It is about 60% autologous versus allogeneic. Cell therapy is still being dominated by ex vivo programs. So, the number of ex vivo programs in the clinic are about 40% of all ex vivo programs. The number of in vivo programs in the clinic, about less than 10%. 10% or less. So, that is where you are still seeing the strength of cell therapy there. T-cells are still a predominant cells that are being engineered. Oftentimes, your CAR-Ts is a majority of that. You see TCRs as well. You are seeing growth in HSCs, growth in TILs as well, growth in NK cells. Across the board, you are seeing that. A few things that have changed as well is the space itself seems to be going after more solid tumors in the oncology space. I think about solid tumors now accounts for 40%-45% of these indications being pursued.

It used to be far less than that. It was more heme or blood cancers that were being pursued. So, I do not know if there is really pockets. It is just more, that is just what the landscape is that we are playing in right now, Hannah.

Moderator

Okay, that is helpful. Then turning to the SPL program revenue side, you recognized an unexpected milestone in 3Q, and you have seen some pretty strong performance from CASGEVY royalties. Can you just talk about what you see going forward on the royalty and milestone front?

Parmeet Ahuja
CFO, MaxCyte

Yeah, certainly a very strong quarter on the non-core side of things. $2 million, as you pointed out, Hannah. $1 million coming from royalties, $1 million from a milestone payment. So, CASGEVY continues to ramp up very well. Their Q3 sales were $99 million, up 30%, I believe, sequentially. 750 patients initiated already. So, as that program scales, we'll be benefactors of that. Very excited to see that progress with our customer, with our partner's program. One change we will be making on the royalty side of things, Hannah, we're going to be moving the royalties reporting as part of core. Given that it's becoming a meaningful part of the business, we want to give investors more visibility into the recurring side. Along with our PAs, licenses, royalties will, we believe, form a big part of that recurring stream and meaningful stream going forward.

Milestones will continue to be reported separately. As you know, they tend to be a bit unpredictable, sort of one time. Looking forward, we expect milestones, again, very much dependent on partner development. Milestones, we expect in 2027 in the very low seven figures. Also because the milestone we received in Q3 was actually expected in 2027. So, there was that pull forward, as typically can happen with milestones.

Moderator

Then, kind of looking a little bit further out, with all of the different pieces of your business, kind of how do you see the business growing across electroporation? You've got preclinical and then SPL customers, multi-platform licenses, SeQure Dx and Akron. Can you just parse out kind of how you see each of these pillars growing over the next few years?

Parmeet Ahuja
CFO, MaxCyte

Yeah. I mean, I think starting off certainly 2027, I've commented on that. Trailing 12-month revenues for PAs, certainly reaching the mid-single digits. Licenses tend to be at the same pace. We expect instruments to be a bit higher than that. CASGEVY royalties continue to ramp up. I think as we look further beyond, Maher-

We've got opportunities with a couple of programs that are in phase III trials.

Maher Masoud
CEO, MaxCyte

Late stage.

Parmeet Ahuja
CFO, MaxCyte

Late stage, getting approved here.

Maher Masoud
CEO, MaxCyte

That's right.

Parmeet Ahuja
CFO, MaxCyte

in the 12 to 18-month timeframe.

Maher Masoud
CEO, MaxCyte

That's right.

Parmeet Ahuja
CFO, MaxCyte

That certainly will ramp up our volumes, revenues in multiple different ways.

Maher Masoud
CEO, MaxCyte

That's exactly right. If I can add to that as well. We expect at least, hopefully, knock on wood, one more program being approved next year. That's a meaningful program for us as well. Potential for, you can have another one possibly, but potential for two more also approved in that early 2028 as well. You look at it, and this is just on the MaxCyte side. You look at Akron, there's potential approval for them next year for those four registrational trials. Same thing again in 2028, potential a few more approvals for them as well. You could look at a time period really in that late 2027, early 2028, where the combined company, we're one company at that point, we're now part of potentially eight to nine commercial programs, right? That's a very different profile than we had in the past.

We also have the multi-platform license model that we have now that's become complementary to the SPL model, which the SPL model is always going to be a mainstay in how we work with biotech companies. But for large pharma, I believe that model that we have with Genentech can be replicated with other large pharmas as well. Truly, we have different ways now really creating that recurring sticky revenue and expanding outside of just non-viral, outside of just non-viral with baby biotechs or mid-sized biotechs. It's an expansion across the entire cell therapy workflow. Viral, non-viral, biotechs, large pharma, highly concentrated commercial revenue. That's what we're looking forward to.

Moderator

Speaking of the multi-platform licenses that you just mentioned, how is the Genentech relationship contributing to revenue, and is this helping drive the kind of recent stabilization we've seen over the last few quarters?

Maher Masoud
CEO, MaxCyte

Do you want to take that, Parmeet?

Parmeet Ahuja
CFO, MaxCyte

Yes, absolutely. We're excited about this model, the pharma model, as we call it. Very exciting contribution certainly here in Q3. We are Genentech's enterprise partner across their cell therapy portfolio. They have two programs in the clinic, many more preclinical, some in research. Truly very excited about the opportunity. Q3 saw a bolus of instruments, PAs, consumables behind those instruments are yet to follow. We'll see some in Q4, but certainly more in 2027. We certainly expect more instruments as well. Truly excited about this opportunity, this model that complements very nicely the small to medium biotech model, what we call the SPL model.

Maher Masoud
CEO, MaxCyte

Mm-hmm. That's right.

Moderator

On that pipeline for additional multi-platform licenses, should we expect more of these in the near term? Is there anything different about the timing that it takes to bring these on? Since they're larger, more complex organizations, does that take longer, or is it a bit faster since they tend to be better funded?

Maher Masoud
CEO, MaxCyte

Yeah. No, great question. The sales cycle is longer. Obviously, large pharma, for example, working with Genentech, this was a 24-month process. We had a bake-off, obviously, between our systems and competing systems. That took 18 months as well. But the whole negotiation was at least a 24-month process. The process takes a little bit longer. Also, it's a little bit different. On the SPL model, you're being spec'd in on a program-by-program basis. With the large pharma model, it's across all the platforms. Whatever they're in the clinic for, whatever preclinical programs they have that they plan to take into the clinic, so it truly becomes a platform model across all of their programs. That takes some time to negotiate as well. The other aspect of it is, and we realize this, there are obviously less large pharmas pursuing cell therapy than the biotechs.

You don't have as many companies that you're pursuing. But I feel, and I have always had a goal that once we work with a big biotech, which we're working with now, we can replicate that, and hopefully we can sign one of these every single year, maybe two, you never know, but one a year at least. But it takes some time. We're talking right now with a few also large pharmas. We see how we can grow with them as well. But again, it's a longer sales cycle, but it's a bigger potential future with these large pharmas as well because you're embedded across their clinical platforms and preclinical platforms.

Moderator

Turning to SeQure Dx, I know this is a small piece of the business, but can you just talk about how this has trended versus your expectations, and could Akron customer relationships further accelerate their sales?

Maher Masoud
CEO, MaxCyte

Sure. Obviously, it's taken a little bit slower than we anticipated with SeQure Dx. We have a recurring licensing revenue from SeQure Dx. The services side has been a little bit lumpy for us, quarter to quarter. I think there's still adoption of SeQure Dx's assays and just the industry itself adopting these assays being done by another company. Oftentimes, companies try to do these assays themselves. We believe they should be done by a SeQure Dx company that are doing it. But there is opportunity there. Obviously, with Akron, we now have exposure to the entire cell therapy market, viral and non-viral. So obviously, that gives us another inroad to be able to go in there and really help with the safety and optimization of these therapies. But the traction has been slow, Hannah. Slow, but it's been steady at the same time.

Moderator

Great. Post-Akron, I think you've mentioned that M&A is kind of off the table for now, any additional M&A. Are there any other areas in the business that need investment, or is the priority just kind of executing from here and integrating that business?

Maher Masoud
CEO, MaxCyte

Sure. Let me take that, and then Parmeet, if you want to add in as well. Obviously, right now, it's about executing on the MaxCyte business, it's about executing on the Akron business, and the integration. As we talked about, the integration will be a light integration, right. They have a very solid team. They're great leadership, great even head of operations, great head of quality. It's about integrating them and really executing there, and continuing to execute. I think now we've been consensus now three straight quarters. We look to keep doing that every quarter, both us and with the acquisition of Akron, doing it now from a combined company. At the same time, there are some investments that we make, and we make them very efficiently.

The same way we launched the DTx earlier this year from an efficient cost basis, there'll be opportunities there where we can continue to look to see how we can expand our offerings, both on the MaxCyte side and the Akron side, from a very efficient perspective as well, how we can increase our offerings. We're always looking to expand and become a broader cell therapy tools provider, which we're now doing. But really, the focus over the next 12 months is just continue to execute, integrate a great company into an already great company, and that's where the focus will be, Hannah.

Moderator

Great. Then finally, Akron is already adjusted EBITDA positive. They should accelerate your path to adjusted EBITDA break-even as a company.

I think you talked about cash burn being less than $10 million next year. How do you view the timeline to cash flow positive now with the combined company?

Maher Masoud
CEO, MaxCyte

Sure. Take this one, Parmeet, but then I want to add at the end.

Parmeet Ahuja
CFO, MaxCyte

Okay.

For sure. Hannah, you've got that very well. We started the year with a guide of about $20 million of cash burn. We've done better. We've kept a real good lid on operating expenses. We're going to exit this year with, I call it legacy MaxCyte, with $17 million burn. Next year, with the contribution of Akron, their EBITDA, their cash flow positive, we expect $7 million-$8 million. That will bring our cash burn, combined company cash burn, along with our efficiencies of $3 million-$4 million, below $10 million, right? We also expect to exit after the transaction is concluded with $40 million-$45 million in cash, providing a very nice runway for our cash burn, which, by the way, we expect will continue to come down as operating leverage takes hold. Top line growing, we don't see a need to increase operating expenses from here.

You can pencil in inflation growth, and that's about it. Then from there, operating leverage does its thing, and we expect as we move into 2028, really exiting 2027, we should be in spitting distance in terms of cash flow positivity.

Maher Masoud
CEO, MaxCyte

Yeah. If I can add to that, I think I'd like to say our track record, I think, shows we can execute on that. I mean, if we take a step back, Hannah, just a few years ago, we used to burn, I think it was $50 million or $50 million plus of annual burn on our own. Now we brought that down to under $20 million in a tough environment, in a truly tough environment. As Parmeet mentioned with the Akron acquisition, there's clearly synergies that we have there where they continue to grow on that. And we have a goal. Our goal is to continue the growth on the top line like we did this year, both on us and on the Akron side, and continue to get to cash flow positivity. That's our goal.

I think you said it, Parmeet, we're within spitting distance, and we can execute towards that. We feel, and this is, we see a few years out where we can have a true company that is specked into multiple commercial programs, highly sticky, highly durable, continuing to grow, and that's where the space is. When you hear cell therapy space has a 20% growth, that comes from being specked in commercial programs. That's where the majority of that growth is coming from, and that's where we're building. In essence, as Parmeet mentioned, we can leverage the scale we have now, both on our side and on Akron's side, without having to increase our operating expenses.

We can double, triple revenues without having to really grow too much as an organization, other than natural inflationary growth, and I'm confident we can do it, and we have the right team. We've taken the last few years, Parmeet joined us from Agilent, and has done a tremendous job, I think, helping me and helping the organization really get to that, I say, maturity of operating as well. We have a fabulous commercial team we've built here. We have people who have brought in from Sartorius, from STEMCELL Technologies, from Thermo and GE. These are leading our North American, European, and our Asia Pacific sales. High-quality regulatory person has joined us as well. It's just we have a great organization we're building here.

Moderator

Well, I think we are out of time now, so thank you for being here today.

Maher Masoud
CEO, MaxCyte

Thank you, Hannah.

Parmeet Ahuja
CFO, MaxCyte

Thank you, Hannah.

Maher Masoud
CEO, MaxCyte

Really appreciate it.

Parmeet Ahuja
CFO, MaxCyte

Appreciate it.

Maher Masoud
CEO, MaxCyte

We'll see you next year.

Moderator

Yes.